Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma

Andrzej J. Jakubowiak, Tara Kendall, Ammar Al-Zoubi, Yasser Khaled, Shin Mineishi, Asra Ahmed, Erica Campagnaro, Christine Brozo, Thomas Braun, Moshe Talpaz, Mark S. Kaminski

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences